Extended Data Fig. 7: Enzalutamide treatment leads to increased cytokine production in tumour specific T cells.
From: Androgen receptor activity in T cells limits checkpoint blockade efficacy
a, Experimental design. Male or female Ripm-OVA animals were implanted with MCA-OVA tumours. Male animals were treated with ADT (degarelix) at time of tumour inoculation. At d7 animals were adoptively transferred with OT1;Thy1.1 CD8 T cells, and half of the animals were started on enzalutamide treatment (5 animals per group). 12 days post adoptive transfer, tumors were harvested, and TILs were stimulated with SIINFEKL peptide followed by ICCS. b, c, Representative flow cytograms showing CD44 and IFNγ expression in OTI T cells in the tumor, and summarized % IFNγ+ and PD-1 MFI in OTI in the tumor in males (b) and females (c). Data representative of 2 independent experiments with 5 animals per group ICCS; intra-cellular cytokine staining. Error bars represent S.E.M. Two-tailed unpaired Student t-test.
